Focus: Citryll is a Netherlands-based biotech company focused on novel treatments targeting neutrophil extracellular trap (NET) formation, with applications in dermatology and immunology.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Citryll to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Citryll
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Citryll's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Candel reports prostate cancer drug’s long-term data ahead of FDA filing - Endpoints News
Candel reports prostate cancer drug’s long-term data ahead of FDA filing Endpoints News
Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013 - GlobeNewswire
Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013 GlobeNewswire
Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013 - Yahoo Finance
Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013 Yahoo Finance
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Showing 5 of 7 publications